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Abstract
Background: Pain is a frequent, yet inadequately explored challenge in patients with systemic sclerosis (SSc). This
study aimed to conduct an extensive pain assessment, examining pain chronification and its association with
disease manifestations.
Methods: Consecutive SSc patients attending their annual assessment were included. SSc-specific features were
addressed as defined by the European Scleroderma Trials and Research (EUSTAR) guidelines. Pain analysis included
intensity, localization, treatment, chronification grade according to the Mainz Pain Staging System (MPSS), general
well-being using the Marburg questionnaire on habitual health findings (MFHW) and symptoms of anxiety and
depression using the Hospital Anxiety and Depression Scale (HADS).
Results: One hundred forty-seven SSc patients completed a pain questionnaire, and 118/147 patients reporting
pain were included in the analysis. Median pain intensity was 4/10 on a numeric rating scale (NRS). The most
frequent major pain localizations were hand and lower back. Low back pain as the main pain manifestation was
significantly more frequent in patients with very early SSc (p = 0.01); those patients also showed worse HADS and
MFHW scores. Regarding pain chronification, 34.8% were in stage I according to the MPSS, 45.2% in stage II and
20.0% in stage III. There was no significant correlation between chronification grade and disease severity, but
advanced chronification was significantly more frequent in patients with low back pain (p = 0.024). It was also
significantly associated with pathological HADS scores (p < 0.0001) and linked with decreased well-being and higher
use of analgesics.
Conclusions: Our study implies that also non-disease-specific symptoms such as low back pain need to be
considered in SSc patients, especially in early disease. Since low back pain seems to be associated with higher
grades of pain chronification and psychological problems, our study underlines the importance of preventing pain
chronification in order to enhance the quality of life.
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Background
Systemic sclerosis (SSc) is a rare autoimmune connective
tissue disease. The pathophysiology is not yet fully
understood but includes vascular and fibrotic changes.
Endothelial, fibroblast and immune system dysregulation
results in vasculopathy, immune cell activation, collagen
accumulation and the presence of autoantibodies. Clin-
ical manifestations are heterogeneous; frequent manifes-
tations are Raynaud’s phenomenon and digital ulcers,
skin fibrosis and joint involvement. Various symptoms
may result from organ involvement of the gastrointes-
tinal tract, lungs, heart or kidneys [1, 2].
Pain is a frequent symptom in SSc patients and can
have various causes. It may for example derive from va-
sospasms, digital ulcerations, synovitis, joint contractures
or gastrointestinal dysmotility. Despite the fact that it is
an important concern for these patients, there is only
very limited data available about pain in SSc [3–6]. Pain
has a major impact on the patient’s activities by impair-
ing physical function [7, 8]. Previous studies have found
that patients with SSc show significantly impaired
health-related quality of life compared to the general
population [9–11]. Several studies found that impaired
quality of life is essentially associated with pain in SSc
patients, emphasizing the importance of adequate pain
therapy in the patient’s treatment [12–14]. Furthermore,
symptoms of anxiety and depression are frequent in SSc
patients and are associated with decreased health-related
quality of life [15]. A review found that between 36 and
65% of all SSc patients show clinically significant symp-
toms of depression [16]. Since pain is significantly asso-
ciated with depressive symptoms in SSc [7, 14],
screening for and treatment of pain is of great import-
ance for these patients.
Despite SSc being a chronic and non-curable disease,
chronification of pain has not been addressed in SSc.
Chronic pain is an important issue in the general popu-
lation with a prevalence between 10 and 44% [17]. A
large survey about chronic pain in Europe showed an
overall point prevalence of 19% and a prevalence of 16%
for Switzerland, with back pain existing in almost half of
the patients [18]. The wide ranges of prevalence are
mainly caused by the lack of a standardized definition.
Chronic pain is often defined as pain that persists for
more than 3 [19] to 6 months [20]. Sometimes, chronic
pain is defined as pain that persists for longer than the
expected duration of healing [19]. More recent findings
imply that pain chronification should be considered as a
multidimensional process with increasing physical, psy-
chological and social problems leading to significant lim-
itations in daily activities [20]. Chronic pain is associated
with depressive symptoms [21, 22] and a meaningfully
decreased health-related quality of life [23–25]. A more
recent literature-based study from 2013 highlights the
high prevalence, individual and societal impact of
chronic pain as well as problems with inadequate treat-
ment and the need for pain treatment education and
guidelines [26].
To assess pain chronification, the Mainz Pain Staging
System (MPSS) is frequently used, showing good validity
in patients with different pain diagnoses [27–29]. This
model considers the multidimensional aspect of chronic
pain, using information on chronological and spatial
qualities of pain as well as information on medication
and the patient’s history. It differentiates between three
stages of pain chronification. Higher stages correspond
to increased pain chronification, typically associated with
permanent, multilocular pain, as well as high usage of
medication and resources of the health system.
In this study, we conducted a detailed pain analysis in
order to learn more about the associations between pain
characteristics, chronification and disease manifestations
in patients with SSc.
Methods
Patients
Consecutive patients with SSc attending the annual assess-
ment programme at the Department of Rheumatology of
the University Hospital Zurich were recruited for this
study. All patients were part of the local European Sclero-
derma Trials and Research (EUSTAR) registry [30].
Patients who reported no pain at all, patients with the
annual clinical assessment more than ± 3months apart
from the pain assessment and patients with rheumatoid
arthritis overlap, potentially influencing pain symptoms
particularly in the hands, were excluded from the
analysis.
We used fulfilment of the different classification cri-
teria as a measure of disease severity and assigned the
patients to three groups: patients who fulfilled both the
1980 American College of Rheumatology (ACR) 1980
criteria [31] for SSc and the ACR/EULAR 2013 classifi-
cation criteria formed the group “established” and pa-
tients fulfilling only the ACR/EULAR 2013 classification
criteria [32] were ascribed to the group “mild”. Patients
who fulfilled neither of these classification criteria but
were clinically diagnosed with SSc by a clinical expert
with long-term experience in SSc (OD and BM) based
on the presence Raynaud’s phenomenon and at least one
of the following features including puffy fingers, positive
antinuclear antibodies or pathological nailfold capillaro-
scopy formed the group “very early”, representing a very
early stage of the disease [33]. Further, we were inter-
ested to analyse how localization of pain affects the SSc
patients; therefore, we compared patients with hand and
back pain as major pain, since those were the most fre-
quent localizations of major pain.
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All patients included in this study had signed informed
consent. The study had been approved by the Cantonal
Ethics Committee (BASEC-Nr 2017-02115).
Measures
Disease characteristics
Information on disease-related symptoms such as skin,
joint and organ involvement was retrieved from the
EUSTAR database and compared amongst the three
groups “established”, “mild” and “very early” for patient
characteristics. Clinical manifestations and organ in-
volvement are defined according to EUSTAR standards
[34]. Disease duration was measured according to the
first occurrence of non-Raynaud’s symptoms. Clinical
signs of arthritis were defined as at least two tender and
swollen joints. Lung fibrosis had to be confirmed by
high-resolution computed tomography (HRCT). Sclero-
derma pattern in nailfold capillaroscopy was defined as
described [35]. To assess skin thickening, the Modified
Rodnan Skin Score (mRSS) was used (a scoring system
of 17 body regions, with maximal score per region of 3
points and maximal mRSS of 51 points) [36].
Hand function
Hand function was assessed with the Cochin Hand
Function Scale (CHFS), which was found to be a valid
and reliable tool in patients with SSc [37, 38]. It consists
of 18 questions about hand function concerning dress-
ing, hygiene, hand ability in the kitchen and at the office
and other daily activities (with 5 levels of difficulty, from
none to impossible).
Pain characteristics
In this study, the German pain questionnaire was used,
which was confirmed to be a valid and reliable tool for
pain assessment [27]. The questionnaire was available in
German, English, French and Italian; the patients could
choose the language they were most familiar with. The
questionnaire contains information on pain localization,
duration, intensity, character and therapies, as well as
questions concerning general well-being and social situ-
ation. Pain intensity is assessed with an 11-point nu-
meric rating scale (NRS) from 0 to 10, with 0 being no
pain and 10 being the worst pain imaginable. Concern-
ing pain localization, patients were asked to distinguish
between their major pain, which has the most severe im-
pact on their life and well-being, and other pain localiza-
tions. Regarding pain medication, analgesics were
differentiated according to the World Health
Organization (WHO) pain ladder [39]. WHO stage I
consists of non-opioids, stage II of mild opioids (e.g.
tramadol, codeine) and stage III of strong opioids (e.g.
oxycodone, morphine, fentanyl). Further, adjuvant medi-
cations such as antidepressants, anticonvulsants and
topical medication were recorded. In the last part of the
questionnaire, the pain chronification grade was assessed
using the MPSS, which showed good construct validity
in previous studies [27–29]. To differentiate between the
three stages of chronification, this model considers four
axes. Chronological aspects are assessed with questions
about pain duration, frequency and change of intensity.
Spatial aspects are considered differentiating whether
pain is localized in one, two or more body sites. Regard-
ing medication, the use of analgesics and potential with-
drawal therapies are assessed. Last, the patient’s personal
history with changes of doctors, pain-related hospitaliza-
tions, surgery and rehabilitation programmes is re-
corded. From the four axes’ sum scores, the total score
and by this, the chronification stage was calculated.
Psychological aspects
Psychological factors were assessed using the Hospital
Anxiety and Depression Scale (HADS), which was
shown to be a good screening instrument for anxiety
and depressive symptoms in patients with non-
psychiatric illnesses [40]. This scale was designed espe-
cially for physically ill patients and does not contain any
somatic symptoms, since they could be caused by the
underlying disease and lead to overestimation [41]. It
consists of 7 questions each for anxiety and depression,
resulting both in a sum score from 0 to 21. In our study,
we considered scores of 11 and more as pathologic and
scores between 8 and 10 as borderline.
The Marburg questionnaire on habitual health findings
(MFHW) [42] was used to assess the patient’s general
well-being, resulting in a score from zero to 35 with
lower scores corresponding to bad well-being. Scores of
10 and below were considered pathological.
Statistical analysis
For statistical analysis, IBM SPSS Statistics, version 2.5,
was used. For nominal data, frequencies were calculated,
and chi-square test or Fisher’s exact test was used for
comparison. For ordinal or continuous data, means with
standard deviation (SD) were calculated in case of nor-
mative distribution; otherwise, medians with first and
third quartiles were calculated. For comparison of or-
dinal or continuous variables, the Mann-Whitney U test
was used for two groups and the Jonckheere-Terpstra
test was used for more than two groups. A p value
smaller than 0.05 was considered significant.
Results
Patient characteristics
Altogether 147 SSc patients completed the question-
naires. Nineteen patients were excluded due to lack of
pain, eight because the clinical assessment was more
than ± 3months apart from the pain assessment, one
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due to overlap with rheumatoid arthritis and one be-
cause the patient did not have SSc. Thus, 118/147
(80.1%) patients reporting pain could be included in this
study. Their clinical characteristics are summarized in
Table 1. The majority of them were females (104/118,
88.1%). The mean age was 57 (± 13.7 SD) years. Sixty-
five (55.1%) patients fulfilled the 1980 ACR criteria for
SSc and were allocated to the group “established”.
Twenty-nine (24.6%) fulfilled only the 2013 classification
criteria and were assigned to the group “mild”. The
remaining 24 (20.3%) patients, who did not yet fulfil any
of these criteria, but had an expert diagnosis of SSc,
formed the group “very early”. The group “established”
contained 31/65 (47.7%) patients with diffuse SSc (dSSc)
according to the classification of LeRoy et al. [43], whilst
there were only patients with limited cutaneous SSc
(lcSSc) in the group “mild”. As expected, the group
“established” showed more symptoms typical for SSc
with more severe skin involvement, worse hand function
and lung organ involvement. Disease manifestations as-
sociated with pain such as active and previous digital ul-
cers (18.5% vs. 3.4%, p = 0.006, and 40.0% vs. 17.2%, p <
0.001, respectively), joint contractures (51.6% vs. 18.2%;
p = 0.002) and subcutaneous calcinosis of the hand
(18.0% vs. 3.6%; p = 0.008) were significantly more fre-
quent in the “established” group than in the “mild”
group. In the “very early” group, digital ulcers and sub-
cutaneous calcinosis were not present.
Pain analysis
Pain intensity does not increase with disease severity
Results for the pain analysis for the three groups “estab-
lished”, “mild” and “very early” are displayed in Table 2.
Overall, median pain intensity during the last 4 weeks
was 4 on an NRS from 0 to 10. There was a numerically
higher NRS in the established group, but this did not
reach statistical significance (p = 0.199). The most fre-
quent localizations patients reported as major pain were
the hands and back, mainly referring to the lumbar
spine. Further frequent pain localizations were the feet
and additional joints of the lower extremity, showing no
significant difference between the groups.
Hand pain is more frequent in advanced disease and
associated with disease-specific symptoms
As expected for SSc patients, the hands were one of the
most frequent localizations of pain. Hand pain in general
was reported by approximately 80% of the patients in all
three groups. As shown in Table 2 and Fig. 1, there was
a difference in the frequency of hand pain as major pain
with 27.3% in the group “very early”, 41.4% in the group
“mild” and 49.2% in the group “established”, although
the difference was not found to be statistically significant
(p = 0.150). Table 3 displays a direct comparison of
patients with main pain in the hands vs. the lower back.
Patients with hand main pain were more often classified
“established” compared to patients with low back main
pain. The median CHFS was 7.0; patients with hand pain
as main pain had higher scores for CHFS (p = 0.001)
than other patients; the same applied for patients who
reported hand pain in general (p < 0.001). Patients
reporting main pain localized in the hands had more fre-
quently digital ulcers (p = 0.008), joint contractures (p =
0.003) and tendon friction rubs (p = 0.013) than other
patients. Similarly, in patients with hand pain, the me-
dian pain intensity was higher when painful digital ische-
mia (p = 0.018; data not shown) or joint contractures
(p = 0.019) were present.
Low back pain is more prevalent in very early disease and
not associated with disease-specific symptoms
Low back as main pain was more frequent in the group
“very early” with 27.3% compared to 17.2% in “mild” and
12.3% in “established” (p = 0.196) (Table 2, Fig. 1). When
not only major pain, but also overall pain was analysed,
the proportion of patients reporting low back pain was
significantly higher in the group “very early” (62.5%
compared to 41.4% in “mild” and 29.2% in “established”;
p = 0.010). As shown in Table 3, patients with low back
pain showed less disease specific symptoms such as
digital ulcers, joint contractures and arthritis in the
hands than patients with hand pain. Accordingly, the
median CHFS was significantly lower in patients with
low back pain than in those without back pain. Regard-
ing major pain, the median value for median pain inten-
sity was 4 in patients with hand pain and 5 in patients
with low back pain.
Low back pain is associated with advanced pain
chronification
Regarding pain chronification, 40/115 patients (34.8%)
were in stage I, 52/115 (45.2%) in stage II and 23/115
(20.0%) in stage III according to the MPSS. Contrary to
our expectations, the proportion of patients with higher
pain chronification stages did not increase with higher
disease severity (Fig. 2). Instead, advanced pain chronifi-
cation was more frequent in patients with low back pain.
For patients with low back pain, the percentage of pa-
tients in MPSS stage III was higher with 42.1% com-
pared to 18.0% in patients with hand pain. There were
only 21.1% in MPSS stage I and 36.8% in stage II com-
pared to 40.0% and 42.0%, respectively, in patients with
hand pain. As major pain, only low back pain was sig-
nificantly more frequent in higher chronification grades
(p = 0.024); in stage III, more than a third of all patients
reported low back pain as their major pain, and approxi-
mately 60% reported low back pain in general (Table 4).
Regarding pain therapy, patients with low back pain
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Table 1 Patient characteristics
Subset of disease manifestation Overall, n = 118 Established, n = 65 (55.1%) Mild, n = 29 (24.6%) Very early, n = 24 (20.3%)
Age (years) 57.1 ± 13.7 56.1 ± 13.6 64.1 ± 9.1 51.3 ± 15.4
Female 104/118 (88.1%) 53/65 (81.5%) 28/29 (96.6%) 23/24 (95.8%)
Disease duration (months) – 82 (42, 246), n = 64 80 (33, 142), n = 21 Not applicable
Subset according to LeRoy
lcSSc – 34/65 (52.3%) 21/21 (100%) Not applicable
dSSc – 31/65 (47.7%) 0/21 (0.0%) Not applicable
Extent of skin involvement (current)
No skin involvement 43/118 (36.4%) 2/65 (3.1%) 19/29 (65.5%) 22/24 (91.7%)
Only sclerodactyly 12/118 (10.2%) 4/65 (6.2%) 7/29 (24.1%) 1/24 (4.2%)
Limited cutaneous involvement 44/118 (37.3%) 40/65 (61.5%) 3/29 (10.3%) 1/24 (4.2%)1
Diffuse cutaneous involvement 19/118 (16.1%) 19/65 (29.2%) 0/29 (0.0%) 0/24 (0.0%)
mRSS 2.5 (0, 9), n = 118 8.0 (4, 15), n = 65 0.0 (0, 2), n = 29 0.0 (0, 0), n = 24
Cochin Hand Function Scale 2.0 (0, 12), n = 65 4.5 (0, 13), n = 48 0.0 (0, 4), n = 21 0.0 (0, 4), n = 16
Disease characteristics
Raynaud’s phenomenon present 115/118 (97.5%) 63/65 (96.9%) 28/29 (96.6%) 24/24 (100%)
Puffy fingers (current) 47/101 (46.5%) 29/48 (60.4%) 17/29 (58.6%) 1/24 (4.2%)
Digital ulcers (current) 13/118 (11.0%) 12/65 (18.5%) 1/29 (3.4%) 0/24 (0.0%)
Digital ulcers (previously) 31/118 (26.3%) 26/65 (40.0%) 5/29 (17.2%) 0/24 (0.0%)
Joint synovitis 24/118 (20.3%) 11/65 (16.9%) 11/29 (37.9%) 2/24 (8.3%)
Clinical signs of arthritis 14/102 (13.7%) 4/51 (7.8%) 8/28 (28.6%) 2/23 (8.7%)
Joint contractures 37/90 (41.1%) 33/64 (51.6%) 4/22 (18.2%) Not available
Tendon friction rubs 5/111 (4.3%) 4/64 (6.3%) 1/28 (3.6%) 0/24 (0.0%)
Subcutaneous calcinosis (hands) 10/101 (9.9%) 9/50 (18.0%) 1/28 (3.6%) 0/23 (0.0%)
Laboratory
ANA 116/118 (98.3%) 64/65 (98.5%) 29/29 (100%) 23/24 (95.8%)
Anti-centromere 57/116 (49.1%) 19/63 (30.2%) 22/29 (75.9%) 16/24 (66.7%)
Anti-Scl-70 23/118 (19.5%) 22/65 (33.8%) 1/29 (3.4%) 0/24 (0.0%)
Anti-RNA polymerase III 12/117 (10.3%) 10/64 (15.6%) 0/29 (0.0%) 2/24 (8.3%)
Anti-U1nRNP 2/116 (1.7%) 2/64 (3.1%) 0/28 (0.0%) 0/24 (0.0%)
Anti-PMScl 8/111 (7.2%) 7/59 (11.9%) 0/28 (0.0%) 1/24 (4.2%)
CRP elevation 15/117 (12.8%) 10/64 (15.6%) 3/29 (10.3%) 2/24 (8.3%)
Organ involvement2
Lung
Dyspnoea present 53/116 (45.7%) 34/64 (53.1%) 13/29 (44.8%) 6/23 (26.1%)
Lung fibrosis on HRCT 39/115 (33.9%) 35/62 (56.5%) 4/29 (13.8%) 0/24 (0.0%)
Function
DLCO (% predicted) 83.6 ± 18.9, n = 116 78.3 ± 20.0, n = 63 88.3 ± 16.6, n = 29 91.8 ± 14.3, n = 24
FVC (% predicted) 101.8 ± 18.6, n = 117 96.1 ± 18.9, n = 64 112.1 ± 16.7, n = 29 104.5 ± 13.9, n = 24
FEV-1 (% predicted) 95.6 ± 19.4, n = 117 90.1 ± 18.9, n = 63 103.3 ± 20.8, n = 29 100.8 ± 14.5, n = 24
TLC (% predicted) 100.9 ± 17.5, n = 87 98.2 ± 17.7, n = 61 106.9 ± 16.7, n = 22 Not available
GIT
Oesophageal symptoms 60/118 (50.8%) 37/65 (56.9%) 15/29 (51.7%) 8/24 (33.3%)
Stomach symptoms 37/91 (40.7%) 26/65 (40.0%) 10/22 (45.5%) Not available
Intestinal symptoms 38/91 (41.8%) 27/65 (41.5%) 10/22 (45.5%) Not available
Evers et al. Arthritis Research & Therapy           (2021) 23:34 Page 5 of 12
showed—consistent with patients in advanced chronifi-
cation stages—higher usage of analgesics, especially
strong opioids, as well as antidepressants.
Symptoms of anxiety and depression are more frequent in
early stages of the disease and are associated with the
presence of low back pain
Overall, 18 out of 107 (16.8%) patients with completed
assessments showed a positive HADS score for anxiety,
and 12 out of 106 (11.3%) patients had a positive HADS
score for depression. As shown in Table 5, the “very
early” group showed the highest percentage of positive
scores for both with 25% each. In addition, the “very
early” group showed more frequently pathological scores
for well-being (30.0% compared to 10.3% in “mild” and
18.0% in “established”). As expected, higher chronifica-
tion grades significantly correlated with higher amounts
of positive HADS scores for anxiety (p < 0.001) as well as
depression (p < 0.001) and with pathologically low scores
for well-being as assessed by the MFHW (p = 0.004).
Table 1 Patient characteristics (Continued)
Subset of disease manifestation Overall, n = 118 Established, n = 65 (55.1%) Mild, n = 29 (24.6%) Very early, n = 24 (20.3%)
CV
Palpitations 12/91 (13.2%) 9/65 (13.8%) 3/22 (13.6%) Not available
Conduction blocks 11/96 (11.5%) 6/47 (12.8%) 4/26 (15.4%) 1/23 (4.3%)
LVEF (%) 63.1 ± 3.9, n = 114 63.1 ± 4.3, n = 64 63.6 ± 3.2, n = 27 62.5 ± 3.8, n = 23
Nailfold capillaroscopy
SSc pattern 90/117 (76.9%) 59/64 (92.2%) 22/29 (75.9%) 9/24 (37.5%)
Immunosuppressive therapy3 26/118 (22.0%) 21/65 (32.3%) 4/29 (13.8%) 1/24 (4.2%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y. Definition of clinical
parameters and organ involvement according to EUSTAR standards [34]
ANA anti-nuclear antibody, Anti-Scl-70 anti-topoisomerase I antibody, CRP C-reactive protein, CV cardiovascular, dSSc diffuse systemic sclerosis, DLCO diffusing
capacity of the lung for carbon monoxide, FEV-1 forced expiratory volume in one second, FVC forced vital capacity, GIT gastrointestinal tract, HRCT high-resolution
computed tomography, lcSSc limited cutaneous systemic sclerosis, LVEF left ventricular ejection fraction, mRSS modified Rodnan Skin Score, n number, RNA
ribonucleic acid, SD standard deviation, SSc systemic sclerosis, TLC total lung capacity, TNF tumour necrosis factor, U1RNP uridine-rich ribonucleic protein
1Skin fibrosis of the face
2In this cohort, none of the patients showed renal crisis
3Including prednisone, cyclophosphamide, methotrexate, azathioprine, mycophenolate, d-penicillamine, rituximab, imatinib mesylate and TNF-alpha inhibitors
Table 2 General pain assessment
Subset of disease manifestation Overall, n = 118 Established, n = 65 (55.1%) Mild, n = 29 (24.6%) Very early, n = 24 (20.3%)
Median pain intensity in the last 4 weeks (NRS)1 4.0 (2, 5), n = 115 4.0 (2, 6), n = 64 3.0 (2, 5), n = 27 3.0 (2, 5), n = 24
Duration since pain symptoms started
Less than 1 year 19/112 (17.0%) 10/62 (16.1%) 8/27 (29.6%) 1/23 (4.3%)
1 to 5 years 55/112 (49.1%) 33/62 (53.2%) 11/27 (40.7%) 11/23 (47.8%)
More than 5 years 38/112 (33.9%) 19/62 (30.6%) 8/27 (29.6%) 11/23 (47.8%)
Most frequent localization for main pain
Back pain 30/116 (25.9%) 14/65 (21.5%) 8/29 (27.6%) 8/22 (36.4%)
Lumbar spine 19/116 (16.4%) 8/65 (12.3%) 5/29 (17.2%) 6/22 (27.3%)
Hand 50/116 (43.1%) 32/65 (49.2%) 12/29 (41.4%) 6/22 (27.3%)
Most frequent localizations for overall pain
Back 71/118 (60.2%) 35/65 (53.8%) 18/29 (62.1%) 18/24 (75.0%)
Lumbar spine 46/118 (39.0%) 19/65 (29.2%) 12/29 (41.4%) 15/24 (62.5%)
Hand 94/118 (79.7%) 52/65 (80.0%) 24/29 (82.8%) 18/24 (78.3%)
Joint of the lower extremity 67/118 (56.8%) 36/65 (55.4%) 14/29 (48.3%) 17/24 (70.8%)
Foot 40/118 (33.9%) 23/65 (35.4%) 10/29 (34.5%) 7/24 (29.2%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
n number, NRS numeric rating scale, SD standard deviation
1Referring to major pain
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From patients in MPSS stage III, 42.9% showed a posi-
tive HADS anxiety score and 28.6% a positive HADS de-
pression score; almost 40% showed pathological scores
for well-being (Table 6). Therefore, since also more of
those patients showed advance chronification grades, pa-
tients with low back pain more often had positive HADS
scores for anxiety (22.2%) and depression (16.7%)
compared to patients with hand pain (8.9% and 6.7%, re-
spectively), which is displayed in Table 7.
Discussion
Our study confirmed that pain is a central problem in
SSc patients. The mean pain intensity was moderate, yet
two thirds of the patients showed pain chronification.
One in five patients met the highest stage of
Fig. 1 Frequencies for the main pain localizations compared
between the groups “very early”, “mild” and “established”, showing a
decrease of back pain and an increase of hand pain with
progressing disease manifestation
Table 3 Hand pain compared to low back pain
Differences in main pain localization Hand pain (n = 50) Low back pain (n = 19)
Age (years) 55.4 ± 14.5 59.0 ± 13.1
Subset of disease manifestation
Very early 6/50 (12.0%) 6/19 (31.6%)
Mild 12/50 (24.0%) 5/19 (26.3%)
Established 32/50 (64.0%) 8/19 (42.1%)
Cochin Hand Function Scale 7.0 (0, 20), n = 35 0.0 (0, 5), n = 14
mRSS 3.5 (0, 16), n = 50 2.0 (0, 7), n = 19
Disease characteristics
Active digital ulcers 9/50 (18.0%) 2/19 (10.5%)
Previous digital ulcers 17/50 (34.0%) 4/19 (21.1%)
Joint synovitis 14/50 (28.0%) 4/19 (21.1%)
Clinical signs of arthritis on the hands 7/43 (16.3%) 1/15 (6.7%)
Joint contractures 25/43 (58.1%) 2/11 (18.2%)
Tendon friction rubs 5/49 (10.2%) 0/19 (0.0%)
Subcutaneous calcinosis of the hands 6/42 (14.3%) 0/15 (0.0%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
mRSS modified Rodnan Skin Score, n number, SD standard deviation
Fig. 2 Distribution of pain chronification stages compared between
the groups “very early”, “mild” and “established”, showing no
association between pain chronification and disease severity
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chronification. Higher grades of pain chronification were
associated with higher HADS scores and higher usage of
analgesics including strong opioids. The observation that
patients with advanced pain chronification more fre-
quently use medication, including opioids, has previously
been shown during the validation of the MPSS [27].
Contrary to our expectations, pain intensity and chroni-
fication were not associated with increased disease sever-
ity. A surprisingly high number of patients reported low
back pain as their major pain, especially in the early
stages of the disease. Those patients also showed in-
creased frequency for symptoms of anxiety and depres-
sion. Hand pain, being associated with typical
scleroderma manifestations like ulcers, joint contractures
and impaired hand function, gained importance with in-
creasing disease severity.
In our study, 87% of the patients reported pain, which
is very similar to a large descriptive study about pain in
SSc that showed 83% of the patients were suffering from
pain [6]. Two smaller studies found 75% [44] and
63% [7] of the patients reporting pain. It must be
noted that in these studies, almost all patients in-
cluded fulfilled the ACR 1980 criteria for SSc, con-
sistent only with the “established” group in our
study. None of the mentioned studies gathered infor-
mation on pain localization or chronification. To our
knowledge, no published study has yet examined the
prevalence of back pain in SSc. Various studies ex-
amined depressive symptoms and their influencing
factors in SSc patients [15, 16]. In our study, symp-
toms of anxiety and depression were significantly
more frequent in patients with very early disease,
which may be due to the increased frequency of low
back pain in this group. Another possible explan-
ation, amongst others, includes the recent diagnosis
of SSc, which could also contribute symptoms of de-
pression and anxiety, as previous studies have shown
in cancer patients [45].
Table 4 Chronification stages
Pain chronification (MPSS), total of patients n = 115 Stage I, n = 40 (34.8%) Stage II, n = 52 (45.2%) Stage III, n = 23 (20.0%)
Age (years) 55.5 ± 15.7 58.6 ± 12.6 56.4 ± 13.4
Average pain intensity in the last 4 weeks (NRS)1 2.0 (1, 3), n = 39 4.0 (2, 5), n = 50 5.0 (4, 7), n = 23
Most frequent localizations for main pain
Back pain overall 9/40 (22.5%) 12/52 (23.1%) 9/23 (39.1%)
Lumbar spine 4/40 (10.0%) 7/52 (13.5%) 8/23 (34.8%)
Hand 20/40 (50.0%) 21/52 (40.4%) 9/23 (39.1%)
Most frequent localizations for overall pain
Back 18/40 (45.0%) 31/52 (59.6%) 20/23 (87.0%)
Lumbar spine 10/40 (25.0%) 20/52 (38.5%) 14/23 (60.9%)
Hand 27/40 (67.5%) 45/52 (86.5%) 21/23 (91.3%)
Joint of the lower extremity 12/40 (30.0%) 35/52 (67.3%) 18/23 (78.3%)
Foot 9/40 (22.5%) 22/52 (42.3%) 9/23 (39.1%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
MPSS Mainz Pain Staging system, n number, NRS numeric rating scale, SD standard deviation
1Referring to major pain
Table 5 Psychological factors according to disease manifestation
Subset of disease manifestation Overall, n = 118 Established, n = 65 (55.1%) Mild, n = 29 (24.6%) Very early, n = 24 (20.3%)
HADS Anxiety Score
Pathological 18/107 (16.8%) 10/61 (16.4%) 3/26 (11.5%) 5/20 (25.0%)
Borderline 21/107 (19.6%) 11/61 (18.0%) 6/26 (23.1%) 4/20 (20.0%)
HADS Depression Score
Pathological 12/106 (11.3%) 7/60 (11.7%) 0/26 (0.0%) 6/20 (25.0%)
Borderline 13/106 (12.3%) 6/60 (10.0%) 4/26 (15.4%) 3/20 (15.0%)
MFHW ≤ 10 20/110 (18.2%) 11/61 (18.0%) 3/29 (10.3%) 6/20 (30.0%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
HADS Hospital Anxiety and Depression Scale, MFHW Marburger Fragebogen zum habituellen Wohlbefinden (Marburg questionnaire on habitual health findings),
n number
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Table 6 Psychological factors and therapy according to chronification stage
Pain chronification (MPSS), total of patients, n = 115 Stage I, n = 40 (34.8%) Stage II, n = 52 (45.2%) Stage III, n = 23 (20.0%)
HADS Anxiety Score
Positive 1/37 (2.7%) 7/46 (15.2%) 9/21 (42.9%)
Borderline 6/37 (16.2%) 9/46 (19.6%) 6/21 (28.6%)
HADS Depression Score
Positive 1/37 (2.7%) 4/45 (8.9%) 6/21 (28.6%)
Borderline 3/37 (8.1%) 4/45 (8.9%) 6/21 (28.6%)
MFHW ≤ 10 3/39 (7.7%) 8/48 (16.7%) 9/23 (39.1%)
Analgesic drug therapy overall 12/40 (30.0%) 30/52 (57.7%) 19/23 (82.6%)
Analgesics WHO I (non-opioids) 12/40 (30.0%) 29/52 (55.8%) 16/23 (69.5%)
Analgesics WHO II (mild opioids) 1/40 (2.5%) 4/52 (7.6%) 7/23 (30.4%)
Analgesics WHO III (strong opioids) 0/40 (0.0%) 1/52 (1.9%) 5/23 (21.7%)
Adjuvant pain medication
Antidepressants 3/40 (7.5%) 9/52 (17.3%) 5/23 (21.7%)
Anticonvulsants 0/40 (0.0%) 2/52 (3.8%) 1/23 (4.3%)
Ambulant examination or therapy by
Pain therapist 1/39 (2.6%) 1/50 (2.0%) 3/23 (13.0%)
Psychiatrist or psychologist 0/39 (0.0%) 3/50 (6.0%) 7/23 (30.4%)
Pain-related stationary treatment 4/34 (11.8%) 13/47 (27.7%) 13/20 (65.0%)
Pain-related stay in rehabilitation facility 2/33 (6.1%) 2/45 (4.4%) 7/19 (36.8%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
HADS hospital anxiety and depression scale, MFHW Marburger Fragebogen zum habituellen Wohlbefinden (Marburg questionnaire on habitual health findings),
MPSS Mainz Pain Staging System, n number, WHO World Health Organization
Table 7 Psychological factors and therapy compared between hand and low back pain
Differences in main pain localization Hand pain (n = 50) Low back pain (n = 19)
HADS Anxiety Score
Positive 4/45 (8.9%) 4/18 (22.2%)
Borderline 7/45 (15.6%) 3/18 (16.7%)
HADS Depression Score
Positive 3/45 (6.7%) 3/18 (16.7%)
Borderline 4/45 (8.9%) 3/18 (16.7%)
MFHW ≤ 10 6/47 (12.8%) 6/19 (31.6%)
Analgesic drug therapy overall 22/50 (44.0%) 15/19 (78.9%)
Analgesics WHO I (non-opioids) 21/50 (42.0%) 12/19 (63.2%)
Analgesics WHO II (mild opioids) 5/50 (10.0%) 4/19 (21.0%)
Analgesics WHO III (strong opioids) 2/50 (4.0%) 3/19 (15.8%)
Adjuvant pain medication
Antidepressants 4/50 (8.0%) 5/19 (26.4%)
Anticonvulsants 0/5 (0.0%) 1/19 (5.3%)
Variables are presented as mean ± SD for normal distribution or as median with the 1st and 3rd quartiles (Q1, Q3) for non-normal distribution. Frequencies are
shown as x/y: x = number of patients with item present, y = numbers of patients with accessible data; missing values can be calculated n − y
HADS Hospital Anxiety and Depression Scale, MFHW Marburger Fragebogen zum habituellen Wohlbefinden (Marburg questionnaire on habitual health findings), n
number, WHO World Health Organization
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Regarding pain chronification, our results show similar
[29, 46] or lower [27, 28, 47] extents of pain chronifica-
tion compared to other studies that used the MPSS in
pain cohorts. A recent study about ambulant and sta-
tionary pain therapy showed a very high extent of pain
chronification, probably indicating an increasing number
of patients with severe chronic pain in such therapy cen-
tres [48]. However, it must be taken into account that
patients in those studies were collected from specialized
pain clinics or practices, whilst only approximately 5% of
the patients in our study reported seeing a pain special-
ist. Supporting our finding that main pain localized on
the lower back was associated with more severe pain
chronification, some of these studies showed that pa-
tients with back pain showed higher grades of pain
chronification [28, 46].
Back pain is a widespread complaint in the general
population; a large multiregional survey in Germany
showed a 1-year prevalence of 75% [49], an investigation
conducted by the Federal Republic of Germany showed
that prevalence rates are increasing [50]. Whilst in the
European guidelines for the treatment of acute non-
specific low back pain it is stated that low back pain is
usually self-limiting and about 90% the patients will re-
cover within 6 weeks [51], other review studies found
that approximately 60% of the patients still suffered from
pain after 1 year [52, 53]. Low back pain leads to psycho-
logical problems for the individual due to its association
with depression [54], but also to a heavy socioeconomic
burden due to the high resulting costs [55, 56]. In order
to avert these negative effects, early assessment of pain
in all its dimensions and adequate multimodal pain
treatment [57] are required. The effectiveness of multi-
modal pain therapy in patients with chronic back pain has
been confirmed [58], showing positive effects for patients of
all MPSS chronification stages. However, significantly less
pain reduction was achieved in patients that have been suf-
fering from back pain for more than 3 years, which under-
lines the importance of early pain assessment. These
implications may also be applied to SSc patients with low
back pain. Fibromyalgia frequently coexists with other
rheumatologic diseases [59]. Low back pain was not specif-
ically addressed in previous studies of SSc patients, yet one
previous study found fibromyalgia—also representing a
non-disease-specific symptom—to be considerably contrib-
uting to disability in SSc patient [60]. Therefore, the possi-
bility of secondary fibromyalgia contributing to low back
pain in SSc patients has to be taken into account.
A recent study about chronic pain in rheumatic dis-
eases has shown a positive effect of multimodal pain
therapy on the patient’s pain-related impairment as well
as physical and mental well-being [61]. However, the
study did not include patients with SSc, and the grade of
pain chronification was not assessed.
Our study has several limitations. For some sub-
analyses, there were missing data and the sample size
was rather small. Due to the cross-sectional study de-
sign, no statements on long-term changes in the
assessed symptoms can be made. Further, we did not
record the source of hand pain; therefore, we could not
differentiate between pain caused by ulcers, Raynaud’s
phenomenon, arthritis or other symptoms. We also did
not have additional information on the specific cause
and associated morphological changes of the lower back
pain in the patients, which needs to be addressed in fur-
ther studies. In addition, we were not able to distinguish
between nociceptive and neuropathic pain, since no vali-
dated screening instrument for neuropathic pain was
used in the questionnaire. Furthermore, there was no
data on the presence of fibromyalgia as a potential con-
founder for pain chronification available in our database.
The fact that we included patients diagnosed with SSc
that did not yet fulfil any classification criteria may be
beneficial, since very early disease stages are considered
in the study, though it makes our patient sample less
comparable to previous publications, where usually the
1980 ACR classification criteria had to be fulfilled as an
inclusion criterion. However, our study is of importance
because it is—according to our knowledge—the first to
conduct such an extensive pain analysis in patients with
SSc, including frequency of pain localizations and the
grading of pain chronification.
It remains unclear why low back pain is more frequent
in the early stages of the disease in this study. A possible
explanation might be the fact that with disease deterior-
ation, other SSc-related pain symptoms such as hand
pain gain priority. As selection bias cannot be ruled out,
further studies examining the prevalence of back pain in
SSc patients will be needed. However, our analysis has
shown that back pain is a very severe problem in pa-
tients with SSc, as it is in the general population.
Conclusions
Taken together, our study has important implications
for the clinical care of SSc patients. To improve treat-
ment and quality of life, early pain assessments should
be conducted in order to detect or prevent pain chronifi-
cation and associated psychological problems. Our study
showed that low back pain is a major driver of pain in
patients with very early disease. It is associated with
higher pain chronification, depression and anxiety and
has therefore major impact on well-being particularly in
this patient group. It therefore needs particular attention
in the care of patients with very early SSc.
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